- Home
- NLOP vs XNCR Comparison
NLOP vs XNCR Comparison
Compare NLOP & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- XNCR
- Stock Information
- Founded
- NLOP N/A
- XNCR 1997
- Country
- NLOP United States
- XNCR United States
- Employees
- NLOP N/A
- XNCR N/A
- Industry
- NLOP
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- NLOP
- XNCR Health Care
- Exchange
- NLOP Nasdaq
- XNCR Nasdaq
- Market Cap
- NLOP 498.8M
- XNCR 547.8M
- IPO Year
- NLOP N/A
- XNCR 2013
- Fundamental
- Price
- NLOP $29.11
- XNCR $8.60
- Analyst Decision
- NLOP Strong Buy
- XNCR Buy
- Analyst Count
- NLOP 1
- XNCR 10
- Target Price
- NLOP $46.00
- XNCR $23.33
- AVG Volume (30 Days)
- NLOP 146.7K
- XNCR 700.0K
- Earning Date
- NLOP 08-06-2025
- XNCR 11-05-2025
- Dividend Yield
- NLOP 10.65%
- XNCR N/A
- EPS Growth
- NLOP N/A
- XNCR N/A
- EPS
- NLOP N/A
- XNCR N/A
- Revenue
- NLOP $117,598,000.00
- XNCR $146,929,000.00
- Revenue This Year
- NLOP N/A
- XNCR $22.06
- Revenue Next Year
- NLOP N/A
- XNCR N/A
- P/E Ratio
- NLOP N/A
- XNCR N/A
- Revenue Growth
- NLOP N/A
- XNCR N/A
- 52 Week Low
- NLOP $26.10
- XNCR $6.92
- 52 Week High
- NLOP $34.53
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- NLOP 29.76
- XNCR 57.89
- Support Level
- NLOP $29.02
- XNCR $8.25
- Resistance Level
- NLOP $29.36
- XNCR $8.73
- Average True Range (ATR)
- NLOP 0.46
- XNCR 0.38
- MACD
- NLOP 0.03
- XNCR 0.07
- Stochastic Oscillator
- NLOP 13.40
- XNCR 78.76
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.